Research highlight: bis-MPA dendrimers evaluated for delivery of anti-cancer drug doxorubicin

As recently published in Biomacromolecules, researchers CQM at Universidade de Madeira report their evaluation of generation 4 and 5 bis-MPA dendrimers as drug delivery vehicles for anti-cancer drug doxorubicin (DOX), as well as the cytotoxicity of the dendrimers toward healthy human cell lines.

The authors report that both hydroxyl and partially amine functionalized dendrimers were cytocompatible, with the dendrimers not affecting the cell viability of lines tested independent of the chemical groups present at the surface.

Moreover, the molecules could be efficiently loaded with DOX, with the partially amine functionalized dendrimers displaying higher loading capacity and fast release of the payload, while the hydroxyl dendrimers were able to release the drug in a more sustained manner. The researchers emphasize that through control of the dendrimer generation and surface functionality, the drug loading and release capacity could be modulated.

The DOX-loaded dendrimers were evaluated against a range of cancer cell lines and human stem cells, confirming that the bis-MPA dendrimers were able to transport DOX to the interior of cancer cells and exert cytotoxic effects.

Read the full paper here.

Polymer Factory are proud to offer materials that are associated with cutting-edge research within dendritic materials and ongoing advances drug delivery and other areas of nanotechnology.

Related Polymer Factory products:

• Bis-MPA Ammonium Dendrimer, Generation 4, TMP Core
• Bis-MPA NHBoc Dendrimer, Generation 4, TMP Core
• Bis-MPA Hydroxyl Dendrimer, Generation 4, TMP Core
• Bis-MPA Hydroxyl Dendrimer, Generation 5, TMP Core

For more information about Polymer Factory, please contact:
Elin Mignérus, CEO
Phone: +46 (0) 79 300 27 76
E-mail: elin.mignerus@polymerfactory.com

Polymer Factory (publ) is a leading global provider and producer of dendritic materials, with customers ranging from BigPharma, MedTech and BioTech companies, to research-intensive institutes and academic research groups. The Company’s dendritic materials act as smart delivery systems that enhance the effects of the substances they carry, e.g. a vaccine or an anticancer drug. They have also shown great promise in diagnostics, tissue engineering and in the development of vaccines. In addition, Polymer Factory has used the Company’s vast knowledge and expertise to develop a patented calibration technology, named SpheriCal®, designed for Mass Spectrometry instruments. The Company’s dendritic nanotechnologies have the potential to accelerate innovation in technologically demanding sectors, such as MedTech and BioTech. Learn more at www.polymerfactory.com.